- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Baillie Gifford & Co. Boosts Beam Therapeutics Stake by 40%
The investment firm increased its holdings in the gene-editing biotech company during Q4 2025.
Apr. 14, 2026 at 7:35am
Got story updates? Submit your updates here. ›
Baillie Gifford's substantial investment in Beam Therapeutics signals institutional confidence in the biotech firm's gene-editing technology and future growth potential.Cambridge TodayBaillie Gifford & Co. lifted its holdings in Beam Therapeutics Inc. (NASDAQ:BEAM) by 39.8% in the fourth quarter, according to the company's recent SEC filing. The fund now owns 416,224 shares of the company's stock, up from 297,803 shares previously.
Why it matters
Beam Therapeutics is a leading biotech firm focused on developing precision genetic medicines using its base editing technology. Increased investment from major institutional investors like Baillie Gifford signals confidence in the company's long-term potential.
The details
Baillie Gifford & Co. added 118,421 shares of Beam Therapeutics to its portfolio during the fourth quarter of 2025, bringing its total stake in the company to 416,224 shares. This represents a 39.8% increase in the firm's holdings. Baillie Gifford now owns 0.41% of Beam Therapeutics, which is valued at $11.5 million.
- Baillie Gifford & Co. increased its Beam Therapeutics stake in Q4 2025.
- Beam Therapeutics is a biotechnology company founded in 2017.
The players
Baillie Gifford & Co.
A global investment management firm based in Edinburgh, Scotland that manages over $400 billion in assets.
Beam Therapeutics Inc.
A biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform, headquartered in Cambridge, Massachusetts.
The takeaway
Baillie Gifford's increased stake in Beam Therapeutics underscores the investment firm's confidence in the biotech company's gene-editing technology and its potential to develop transformative precision medicines.
